JP2003513045A5 - - Google Patents

Download PDF

Info

Publication number
JP2003513045A5
JP2003513045A5 JP2001534385A JP2001534385A JP2003513045A5 JP 2003513045 A5 JP2003513045 A5 JP 2003513045A5 JP 2001534385 A JP2001534385 A JP 2001534385A JP 2001534385 A JP2001534385 A JP 2001534385A JP 2003513045 A5 JP2003513045 A5 JP 2003513045A5
Authority
JP
Japan
Prior art keywords
antagonist
opioid antagonist
composition according
small intestine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001534385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003513045A (ja
Filing date
Publication date
Priority claimed from GB9925872A external-priority patent/GB9925872D0/en
Priority claimed from GB9928314A external-priority patent/GB9928314D0/en
Application filed filed Critical
Priority claimed from PCT/GB2000/004167 external-priority patent/WO2001032180A2/en
Publication of JP2003513045A publication Critical patent/JP2003513045A/ja
Publication of JP2003513045A5 publication Critical patent/JP2003513045A5/ja
Pending legal-status Critical Current

Links

JP2001534385A 1999-11-01 2000-10-30 便秘及び過敏性大腸症候群を治療・処置するための組成物 Pending JP2003513045A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9925872.5 1999-11-01
GB9925872A GB9925872D0 (en) 1999-11-01 1999-11-01 Composition for relief of constipation
GB9928314.5 1999-11-30
GB9928314A GB9928314D0 (en) 1999-11-30 1999-11-30 Composition for the treatment of irritable bowel syndrome
PCT/GB2000/004167 WO2001032180A2 (en) 1999-11-01 2000-10-30 Composition for treatment of constipation and irritable bowel syndrome

Publications (2)

Publication Number Publication Date
JP2003513045A JP2003513045A (ja) 2003-04-08
JP2003513045A5 true JP2003513045A5 (enExample) 2007-11-01

Family

ID=26316047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534385A Pending JP2003513045A (ja) 1999-11-01 2000-10-30 便秘及び過敏性大腸症候群を治療・処置するための組成物

Country Status (13)

Country Link
US (1) US6734188B1 (enExample)
EP (1) EP1225897B1 (enExample)
JP (1) JP2003513045A (enExample)
AT (1) ATE275402T1 (enExample)
AU (1) AU776567B2 (enExample)
CA (1) CA2389650C (enExample)
CZ (1) CZ299726B6 (enExample)
DE (1) DE60013630T2 (enExample)
DK (1) DK1225897T3 (enExample)
ES (1) ES2226933T3 (enExample)
IL (2) IL149378A0 (enExample)
PT (1) PT1225897E (enExample)
WO (1) WO2001032180A2 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
WO2001032180A2 (en) 1999-11-01 2001-05-10 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
PL2278002T3 (pl) * 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
SI1931316T1 (sl) * 2005-08-15 2010-06-30 Solvay Pharm Gmbh Farmacevtski sestavki z nadzorovanim sproščanjem za kislinsko labilna zdravila
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
EA200870449A1 (ru) * 2006-04-19 2009-04-28 Джилл П. Смит Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
WO2008033125A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
WO2008033124A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
CA2702680A1 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CN102014907A (zh) * 2008-05-07 2011-04-13 尼克塔治疗公司 外周作用阿片拮抗剂的口服给药
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
CA2759870A1 (en) * 2009-04-22 2010-10-28 Phoeme Gmbh Particulate pharmaceutical composition with an opioid and an opioid antagonist
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
KR20160034352A (ko) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
JP6232135B2 (ja) 2013-11-13 2017-11-15 ユーロ−セルティーク エス．エイ． 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003197A1 (en) * 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
IT1188550B (it) * 1986-02-07 1988-01-14 Sclavo Spa Peptide sintetico ad attivita' interleukina 1 umana
US4774230A (en) 1988-03-26 1988-09-27 Ivax Laboratories, Inc. Glucuronic acid derivatives of opioid antagonists
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
IT1298575B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
WO2000003660A1 (en) 1998-07-17 2000-01-27 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
WO2001032180A2 (en) 1999-11-01 2001-05-10 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome

Similar Documents

Publication Publication Date Title
CA2389650C (en) Composition for treatment of constipation and irritable bowel syndrome
AU718052B2 (en) Intestinal absorption of nicotine to treat nicotine responsive conditions
ES2412409T3 (es) Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
RU2211047C2 (ru) Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
US7374779B2 (en) Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
DE69729579D1 (de) Polymer-lipide mikroverkapselte gase und ihre anwendung bei bilderzeugenden mitteln
WO2003013433A3 (en) Sequestered antagonist formulations
JP7296185B2 (ja) 重水素化ドンペリドン組成物及び疾患の治療方法
UA88056C2 (uk) Дозована форма оксикодону, що вводиться один раз на день
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
ATE389389T1 (de) Mehrfach beschichete pharmazeutische dosierungsform
WO2007111945A2 (en) Method for management of diarrhea
WO2006133349A2 (en) Orally disintegrable sleep aid formulations
JP2003508434A5 (enExample)
JP2004529207A (ja) Ｌｈｒｈアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療
AU780379B2 (en) Orally distintegrating composition comprising mirtazapine
NL8900734A (nl) Vaste, snel uiteenvallende toedieningsvormen.
EA200100869A1 (ru) Кристаллическая форма эплеренона
CN1124454A (zh) 组合物
JP4854115B2 (ja) 無水パロキセチン用安定製剤形
HK1048595B (en) Composition for treatment of constipation and irritable bowel syndrome